COMMUNIQUÉS West-GlobeNewswire

Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
06/07/2017
Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx ® versus Stelara ® in psoriasis [1],[2] Update also includes use of Cosentyx in moderate-to-severe scalp psoriasis[1 [...]
Shire plc : Additional Listing
06/07/2017
Additional Listing July 6, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") hereby notifies the market that an application has been made to the London Stock Exchange and the UK Listing Authority for a total of [...]
MITHRA STRENGTHENS E4 PATENT POSITION IN AUSTRALIAN MARKET
06/07/2017
PRESS RELEASE MITHRA StRENGTHENS E4 PATENT POSITION in australiaN MARKET Patents granted for Estetrol (E4) synthesis protect manufacturing process until 2032 Certificate of grant covers E4's use alone as an emergency [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
06/07/2017
pdf version of the press release This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]
MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test
06/07/2017
Study reports test could reduce invasive diagnostic procedures by 77% NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 6, 2017 - MDxHealth SA (Euronext: MDXH. [...]
MDxHealth lance AssureMDx, un test de biopsie liquide pour la détection du cancer de la vessie
06/07/2017
Une étude révèle que le test pourrait réduire les techniques invasives de diagnostic de 77 % COMMUNIQUE DE PRESSE / INFORMATION REGLEMENTAIRE / INFORMATION PRIVILEGIEE IRVINE, CA, and HERSTAL, BELGIQUE - 07:00 CEST, 6 [...]
Le candidat-médicament QRX-411 de ProQR pour le syndrome d'Usher obtient la désignation d'Orphan Drug (médicament orphelin) de la FDA et de l'EMA
06/07/2017
Principaux résultats Le QRX-411 de ProQR obtient la désignation Orphan Drug (médicament orphelin) par la FDA et l'EMA pour le traitement de la rétinite pigmentaire, y compris le syndrome d'Usher, le sous-type ciblé par [...]
Taconic Biosciences and Pharmatest Services Ltd. Create First Human Immune System Model for Bone Metastasis
05/07/2017
Researchers hopeful this new model will address incurable and painful disease HUDSON, N.Y., July 05, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated [...]
ETC's Sterilization Systems Group Awarded Eight Contracts
05/07/2017
For Immediate Release SOUTHAMPTON, PA, USA , July 5, 2017 - Environmental Tectonics Corporation's (OTC Pink: ETCC) ("ETC" or the "Company") Sterilization Systems Group ("SSG") today announced that calendar year to date [...]
Bilan semestriel du contrat de liquidité DBV Technologies contractés avec Natixis
05/07/2017
Informations Réglementées Montrouge, France, le 05 juillet 2017, 22h30 CEST Bilan semestriel du contrat de liquidité DBV Technologies contractés avec Natixis Montrouge, France le 5 juillet 2017 - Au titre du contrat de [...]
Half-Year Report on the DBV Technologies Liquidity Contract with Natixis
05/07/2017
AMF REGULATED INFORMATION Montrouge, France, July 5, 2017 Half-Year Report on the DBV Technologies Liquidity Contract with Natixis Under the liquidity contract between DBV TECHNOLOGIES and NATIXIS, the following assets [...]
Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
05/07/2017
WALTHAM, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced public offering of 5,750, [...]
Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease
05/07/2017
First potentially disease-modifying anti-alpha-synuclein antibody to be evaluated for efficacy in patients with Parkinson's disease Prothena to receive $30 million milestone payment under collaboration agreement with [...]
Arques Clinic : FAB Generation: Fabulous at Fifty and Beyond
05/07/2017
MARBELLA, SPAIN--(Marketwired - Jul 5, 2017) - Being 50 years old has really changed in the last 20 years and now doesn't feel that old. The classic stereotype is being replaced by a new standard: the Fabulous at Fifty [...]
Nature Publication Reports Favorable Clinical Trial Results of BioNTech's Individualized Cancer Vaccine IVAC® MUTANOME
05/07/2017
- First-ever clinical study demonstrates personalized RNA-based vaccine using mutant neo-epitopes as antigens activates immune system against individual mutations and exerts anti-cancer activity - MAINZ, Germany, July [...]
Essilor : Nombre total de droits de vote et d'actions composant le capital social au 30 juin 2017
05/07/2017
Nombre total de droits de vote et d'actions composant le capital social au 30 juin 2017 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton-le-Pont, France ( [...]
Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of June 30, 2017
05/07/2017
Disclosure of Share Capital and Voting Rights Outstanding as of June 30, 2017 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Deinove : le processus d'industrialisation du programme caroténoïdes entre en phase II
05/07/2017
DEINOVE : LE PROCESSUS D'INDUSTRIALISATION DU PROGRAMME CAROTÉNOÏDES ENTRE EN PHASE II La Phase I du programme a permis de sélectionner la première molécule caroténoïde qui sera produite à échelle industrielle courant [...]
Deinove: the industrialization process of the carotenoids program enters phase II
05/07/2017
DEINOVE: THE INDUSTRIALIZATION PROCESS OF THE CAROTENOIDS PROGRAM ENTERS PHASE II Phase I of the program selected the first carotenoid molecule to be produced on an industrial scale in 2018. The yields obtained in 20- [...]

Pages